Frontiers in Cardiovascular Medicine

JULY 15, 2025

ConclusionElevated plasma TAT complex levels are strongly associated with CSF and may serve as a candidate diagnostic biomarker. More specifically, ROC analysis revealed that a plasma TAT complex levels of 3.875 ng/ml predicted CSF with a specificity of 89.2% and a sensitivity of 62.6%.ConclusionElevated

Biomarkers 52

Biomarkers Myocardial Infarction Cholesterol Thrombolysis 52

Frontiers in Cardiovascular Medicine

JUNE 20, 2025

The serum homocysteine-to-albumin ratio (HAR) is a novel biomarker that combines oxidative stress and inflammatory processes, both of which play key roles in cardiovascular pathophysiology. ConclusionsHAR is a strong and independent predictor of MACE in AMI patients.

Myocardial Infarction 52

Myocardial Infarction Biomarkers Laboratory Heart Failure 52

Frontiers in Cardiovascular Medicine

APRIL 3, 2025

Identifying novel biomarkers is crucial to improving early detection and patient classification. Traditional markers such as cardiac troponins have limitations, including delayed detectability in blood samples, necessitating the search for better alternatives. ng/ml) compared to healthy individuals (3.821.20 ng/ml, P<0.001).

Biomarkers 52

Biomarkers Outcomes Research 52

Frontiers in Cardiovascular Medicine

FEBRUARY 13, 2025

Additionally, HSPA2 and GEM showed significant associations with a wide range of immune cells.DiscussionHSPA2 and GEM can function as diagnostic biomarkers for unstable coronary atherosclerotic plaques. IntroductionDecreased stability of coronary atherosclerotic plaques correlates with a heightened risk of acute coronary syndrome (ACS).

Plaque 52

Plaque Biomarkers Research 52

Frontiers in Cardiovascular Medicine

FEBRUARY 13, 2025

Biomarkers commonly used in both silicosis and cardiovascular diseases were reviewed to underline the common pathological pathways.ResultsPublished epidemiological data revealed a higher risk of ischemic heart disease, stroke, and hypertension in silica-exposed workers, even at low exposure levels.

Myocardial Infarction 52

Myocardial Infarction Biomarkers Cardiovascular Disease Pericarditis 52

Frontiers in Cardiovascular Medicine

APRIL 14, 2025

Conventional biomarkers, while effective for a number of patient groups, fail to provide personalized diagnosis and prognosis, necessitating the exploration of novel markers. Recent attention has turned to a subset of cfDNA, circulating bacterial DNA (cbDNA), derived from gut microbiota, as a potential biomarker.

Cardiovascular Disease 52

Cardiovascular Disease Circulation Biomarkers Risk Factors 52

Frontiers in Cardiovascular Medicine

JULY 16, 2025

BackgroundGalectin-3 is a well-established biomarker on the predictor of cardiovascular events in patients with heart failure.

Stents 52

Stents Stent Coronary Artery Disease Outcomes 52

Nature Reviews - Cardiology

FEBRUARY 2, 2025

Nature Reviews Cardiology, Published online: 03 February 2025; doi:10.1038/s41569-025-01132-3 In this Clinical Outlook, we describe available multiomic studies in cardiovascular medicine, discuss the advantages and potential of multiomic techniques for clinical translation in cardiology, and highlight three promising aspects: the generation of unprecedented (..)

Biomarkers 84

Biomarkers 84

Frontiers in Cardiovascular Medicine

JUNE 26, 2025

Advanced imaging techniques, notably the perivascular fat attenuation index (FAI) and circulating biomarkers, are highlighted for early CVD detection. We explore PVAT's molecular interactions in obesity, diabetes, and hypertension, elucidating its contribution to inflammation, oxidative stress, and endothelial dysfunction.

Cardiovascular Disease 52

Cardiovascular Disease Pharmacology Biomarkers Obesity 52

Frontiers in Cardiovascular Medicine

MAY 29, 2025

Hub biomarkers were determined by intersecting DEGs, proteinprotein interaction networks, and WGCNA results. Molecular docking validated interactions between DYX components and hub biomarkers. Single-cell RNA sequencing analyzed hub biomarker expression in coronary plaques.ResultsFOS was a core biomarker for DYX for MI.

Myocardial Infarction 40

Myocardial Infarction Biomarkers Pharmacology Research 40

Open Heart

JANUARY 31, 2025

Early identification and characterisation of embolic risk factors, including vegetation size, mobility and echogenicity assessed through transthoracic and transoesophageal echocardiography, but also certain pathogens and biomarkers are important for guiding clinical decisions.

Embolism 52

Embolism Biomarkers Heart Failure Risk Factors 52

Frontiers in Cardiovascular Medicine

JULY 18, 2025

Particular emphasis is placed on the role of TyG-BMI index in influencing disease progression, highlighting its potential as a transformative biomarker for risk stratification and therapeutic targeting across diverse medical disciplines.

BMI 52

BMI Research Coronary Artery Disease Biomarkers 52

European Journal of Heart Failure

MAY 25, 2025

Association of ventriculararterial coupling with heart failure (HF) biomarkers in the STANISLAS cohort. The extent of the relationship between VAC and circulating biomarkers associated with HF has been scarcely documented. MMP, matrix metalloproteinase; NT-proBNP, N-terminal pro-B-type natriuretic peptide.

Heart Failure 40

Heart Failure Biomarkers Document Circulation 40

Frontiers in Cardiovascular Medicine

JULY 15, 2025

These findings highlight their potential as biomarkers of atrial remodeling and implicate key molecular pathways involved in AF pathogenesis.

Atrial Fibrillation 52

Atrial Fibrillation Circulation Biomarkers Heart Failure 52

Cardiovascular Diabetology

JULY 2, 2025

Coronary Heart Disease (CHD) and Non-Alcoholic Fatty Liver Disease (NAFLD) share overlapping pathogenic mechanisms including adipose tissue dysfunction, insulin resistance, and systemic inflammation mediated b.

Biomarkers 64

Biomarkers Heart Disease Research 64

Frontiers in Cardiovascular Medicine

JULY 9, 2025

Its ability to simultaneously reflect renal dysfunction, malnutrition, and inflammation highlights its potential as a valuable biomarker for risk stratification.

Heart Failure 52

Heart Failure Biomarkers Cardiac Function Hospital 52

Medical Xpress - Cardiology

JUNE 16, 2025

During physical exertion, the protein troponin is released—a biomarker indicative of cardiac damage. Exercising is healthy, but it also puts strain on the heart. New research from Radboudumc involving a thousand athletes shows that elevated troponin levels after exercise are not due to coronary atherosclerosis.

Exercise 40

Exercise Atherosclerosis Biomarkers Research 40

Frontiers in Cardiovascular Medicine

APRIL 21, 2025

Machine learning models, including Random Forest and Support Vector Machine (SVM), were applied to select potential AF-related diagnostic biomarkers, and validated in the animal model (beagles; n=6).ResultsA Correlation analysis and WGCNA were performed to assess interactions between lactylation-related genes and immune-associated DEGs.

Atrial Fibrillation 52

Atrial Fibrillation Biomarkers Heart Failure Arrhythmia 52

Frontiers in Cardiovascular Medicine

JUNE 24, 2025

Although research on the role of EVs in AS and the role of biomarkers or drug carriers in clinical practice has been expanding, several challenges remain for clinical applications, including the lack of specific therapeutic targets for EVs, flaws in the separation and purification processes, and limited clinical trial data on their safety.

Cardiovascular Disease 52

Cardiovascular Disease Atherosclerosis Plaque Biomarkers 52

Journal of the American Heart Association

MAY 2, 2025

Machine learning models based on metabolic biomarkers were constructed to screen CHD in neonates.ResultsAfter quality control, 22 539 neonates were ultimately included. We constructed CHD and ventricular septal disease screening models based on metabolic biomarkers.

Congenital Heart Disease 45

Congenital Heart Disease Congenital Heart Disease Biomarkers 45

Journal of Clinical Investigation - Cardiology

MAY 1, 2025

Recent biomarker evidence suggests alternative pathway activation in this setting. In this manuscript, we review the impact of reduced kidney function on biomarkers of the alternative complement pathway and the implications of alternative pathway activation on cardiovascular disease and kidney disease progression.

Kidney Disease 93

Kidney Disease Biomarkers Cardiovascular Disease Research 93

Heart BMJ

JANUARY 29, 2025

Background We evaluated the potential of circulating bone morphogenetic protein 10 (BMP10) as a biomarker for atrial stress and remodelling in patients with heart failure (HF), in comparison to N-terminal pro-B-type natriuretic peptide (NT-proBNP). We also assessed the predictive value of BMP10 for adverse clinical outcomes.

Heart Failure 52

Heart Failure Circulation Biomarkers Atrial Fibrillation 52

Frontiers in Cardiovascular Medicine

JULY 10, 2025

ObjectiveThis study aims to investigate the prognostic value of integrating inflammatory biomarkers with the established Global Registry of Acute Coronary Events (GRACE) risk score for predicting clinical outcomes in patients with myocardial infarction (MI).MethodsThis The Gensini score and GRACE score were calculated for each patient.

Myocardial Infarction 59

Myocardial Infarction Biomarkers Risk Factors Strokes 59

Frontiers in Cardiovascular Medicine

JULY 10, 2025

The benefits of HDL may yet be revealed by the use of these new high-throughput RCT assays perhaps as a screening tool for novel RCT boosting agents or as new biomarkers for cardiovascular disease risk.

Cholesterol 52

Cholesterol Biomarkers Cardiovascular Disease Research 52

Circulation: Genomic and Precision Medicine

JUNE 16, 2025

RESULTS:Genetic variants representing distinct AF-related mechanistic pathways had significantly different effects on several AF-related phenotypes.

Genetic predisposition 40

Genetic predisposition Atrial Fibrillation Strokes Stroke 40

Frontiers in Cardiovascular Medicine

NOVEMBER 25, 2024

BackgroundAtherosclerosis, a complex chronic vascular disorder with multifactorial etiology, stands as the primary culprit behind consequential cardiovascular events, imposing a substantial societal and economic burden. Nevertheless, our current understanding of its pathogenesis remains imprecise.

Atherosclerosis 59

Atherosclerosis Biomarkers Plaque Hypertension 59

Frontiers in Cardiovascular Medicine

JUNE 13, 2025

ConclusionsPVAT attenuation, reflected by HUΔ and HUratio, serves as a significant, non-invasive imaging biomarker for predicting residual false lumen formation after TEVAR in TBAD patients. vs. 5.16 ± 2.84, P   7.170 (sensitivity 0.895, specificity 0.762) and HUratio ≤ 0.790 (sensitivity 0.947, specificity 0.667).ConclusionsPVAT

Aortic 52

Aortic Biomarkers Outcomes Hospital 52

Frontiers in Cardiovascular Medicine

MAY 18, 2025

Cardiovascular diseases (CVD) remain the primary cause of morbidity and mortality in developed countries, highlighting the urgent need to identify biomarkers associated with CVD and its risk factors.

Cardiovascular Disease 52

Cardiovascular Disease Coronary Artery Disease Risk Factors Diabetes 52

Frontiers in Cardiovascular Medicine

DECEMBER 18, 2024

The content of EVs can also indicate the status of their parental cells and serve as a biomarker for monitoring the risk of cardiac injury. Examining these vesicles can offer fresh perspectives on the development of MI and assist in creating innovative treatments.

Myocardial Infarction 52

Myocardial Infarction Physiology Innovation Biomarkers 52

Medical Xpress - Cardiology

JUNE 30, 2025

A new study shows the promise of a biomarker that could allow doctors to replace these invasive biopsies with a simple blood test. Following a heart transplant, patients must undergo surgical biopsies so that clinicians can monitor for signs of organ rejection. The results are published in the journal Transplantation.

Heart Transplant 40

Heart Transplant Transplant Biomarkers 40

Frontiers in Cardiovascular Medicine

DECEMBER 22, 2024

Novel serum biomarkers can potentially help in early detection and estimation of postoperative outcomes. BackgroundAcute aortic dissection is a lethal cardiovascular emergency; early diagnosis is critically necessary. ResultsYAP concentration was substantially elevated among ATAAD patients [3.45 (3.18, 3.63) vs. 2.44 (2.23, 2.59), P<0.01].

Aortic 52

Aortic Chest Pain Biomarkers Circulation 52

Circulation: Genomic and Precision Medicine

JUNE 13, 2025

These findings may help advance genotype-driven biomarker discovery and tailored therapeutic development inLMNADCM.

Cardiomyopathy 74

Cardiomyopathy Biomarkers Heart Failure Circulation 74

Journal of Cardiovascular Pharmacology

JULY 17, 2025

Further longitudinal studies and biomarker-based surveillance are needed to quantify cumulative risk. Further longitudinal studies and biomarker-based surveillance are needed to quantify cumulative risk. Despite the availability of safer alternatives, regulatory responses are inconsistent and clinical awareness is limited.

Biomarkers 40

Biomarkers Cardiovascular Disease Article 40

European Journal of Heart Failure

JULY 14, 2025

Physiological postpartum remodelling and the pathological processes involved in peripartum cardiomyopathy (PPCM).

Cardiomyopathy 45

Cardiomyopathy Biomarkers Document Physiology 45

Frontiers in Cardiovascular Medicine

APRIL 23, 2025

In addition, Baduanjin exercise improved blood biomarkers such as NT-proBNP (MD: 183.83, 95% CI: 309.83 The secondary outcomes also demonstrated benefits in cardiac remodeling indices, including reductions LVESD (MD: 1. 67, 95% CI: 2.76 to 0.59, p=0.002, I2=95%), LVDD (MD: 2.38, 95% CI: 3.59 to 1.17, p=0.0001, I2=93%).

Exercise 52

Exercise Cardiovascular Disease Cardiac Function Biomarkers 52

Stroke Journal

JUNE 25, 2025

Biomarker-guided protocols: VNS for cortical/subcortical ischemic deficits and FNS for cerebellar network recovery are advocated to address postischemic disability via anti-inflammatory rewiring, neuroplasticity enhancement, and cerebellar-thalamocortical circuit stabilization.

Strokes 40

Strokes Stroke Biomarkers Hemorrhage 40

CardiacWire

JULY 11, 2025

From AccurKardia’s ECG-based AI-powered AK+ Guard hyperkalemia detection software, to Anumana’s ECG-AI integration with AliveCor’s Kardia ECGs, the trend is clear – ECGs can be used as a broad biomarker with AI’s help.

AFIB 52

AFIB Ablation Innovation Biomarkers 52